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Decreased expression of caveolin-1 in Systemic Sclerosis: crucial 
role in the pathogenesis of tissue fibrosis 
 
Francesco Del Galdo, MD, PhD1, Federica Sotgia, PhD2, Cecilia de Almeida, PhD2, Jean- 
Francois Jasmin, PhD2, Megan Musick, BS1, Michael Lisanti, MD, PhD2, and Sergio A. 
Jimenez, MD1 
1Jefferson Institute of Molecular Medicine, Thomas Jefferson University, 233 s 10th street, 19107 
Philadelphia-PA 
2Kimmel Cancer Center, Thomas Jefferson University, 233 s 10th street, 19107 Philadelphia-PA 
 
Abstract 
 
Purpose—Recent studies have implicated caveolin-1 (cav-1), in the regulation of transforming 
growth factor-β (TGF-β) downstream signaling. Given the crucial role of TGF-β in the pathogenesis 
of Systemic Sclerosis (SSc) we examined here whether cav-1 is also involved in the pathogenesis of 
tissue fibrosis in SSc. We analyzed the expression of cav-1 in affected SSc tissues, studied the effects 
of lack of expression of cav-1 in vitro and in vivo, and analyzed the effects of restoration of cav-1 
function on the fibrotic phenotype of SSc fibroblasts in vitro. 
 
Methods—Cav-1 expression in tissues was analyzed by immunofluorescence and confocal 
microscopy. Extent of tissue fibrosis in cav-1 knockout mice was assessed by histology/ 
histochemistry and quantified by hydroxyproline assays. Cav-1 null and SSc fibroblast phenotype 
and protein production were analyzed by real time PCR, immunofluorescence, Western blots and 
Multiplexed ELISA. The effects of cav-1 function restoration in SSc fibroblasts in vitro were also 
examined employing a cell permeable recombinant cav-1 peptide. 
 
Results—Cav-1 is markedly decreased in affected lungs and skin from SSc patients. Cav-1 
knockout mice develop pulmonary and skin fibrosis. Cav-1 downregulation is maintained in cultured 
SSc fibroblasts and restoration of cav-1 function in vitro normalizes their phenotype and abrogates 
TGF-β stimulation through inhibition of Smad3 activation. 
 
Conclusions—Caveolin-1 appears to participate in the pathogenesis of tissue fibrosis in SSc. 
Restoration of cav-1 function by treatment with a cell permeable peptide corresponding to the cav-1 
scaffolding domain may be a novel therapeutic approach in SSc. 
 
Introduction 
 
Systemic sclerosis (SSc) is characterized by excessive deposition of collagen and other 
connective tissue macromolecules in skin and multiple internal organs, prominent and often 
severe alterations in the microvasculature, and humoral and cellular immunologic 
abnormalities (1). The excessive collagen deposition in SSc is due to overproduction of this 
protein by fibroblasts (2-4). Indeed, it is the persistent activation of the genes encoding various 
collagens in SSc fibroblasts that distinguishes controlled repair, such as that occurring during 
normal wound healing, from the uncontrolled fibrosis that is the hallmark of SSc (5). Numerous 
 
 
 
Address all the correspondence to: Sergio A. Jimenez, MD, Jefferson Institute of Molecular Medicine, Thomas Jefferson University, 
Suite 509, Bluemle Life Sciences Bldg., Philadelphia, PA. 19107, Phone (215)503-5042, Fax: (215)923-4649, e-mail: 
Sergio.jimenez@jefferson.edu. 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
Galdo et al. Page 2 
 
alterations in the expression of cytokines and growth factors with potent effects on fibroblast 
collagen synthesis, various endothelial cell functions, and T cell responses have been 
demonstrated in SSc (6-8). Transforming growth factor β (TGF-β) is a growth factor that plays 
a crucial role in tissue fibrosis (9-12) and it has been implicated in the pathogenesis of SSc 
(1,12-17). An important effect of TGF-β is the stimulation of the expression of genes encoding 
various collagens and other matrix proteins and the processing and tissue deposition of 
interstitial collagens (9-11). Although SSc fibroblasts display increased TGF-β signaling (18, 
19), the mechanisms responsible are not completely known. A recent study confirmed the 
importance of the increased TGF-β pathway activation in SSc pathogenesis. In this study the 
conditional, fibroblast-specific gene expression of a constitutively active TGF-β Receptor-1 
(TGFβR-1) recapitulated the fibrotic process occurring in the skin, the vasculature and possibly 
the lung of SSc patients (20). 
 
Caveolin 1 (cav-1) is the most important member of a family of membrane proteins that are 
the major coating proteins of caveolae. Caveolae are 50- to 100-nm flask-shaped invaginations 
which represent a morphologically identifiable subset of lipid rafts (21). The spatial 
organization of cell receptors in lipid rafts can modulate the subsequent transmission of the 
specific signal (22,23). Indeed, TGF-β 1 receptors are internalized both by cav-1 associated 
lipid rafts and by early endosome antigen 1 non-lipid raft 1 pathways. Non-lipid raft associated 
internalization increases TGF-β signaling, whereas, caveolin-associated internalization 
increases TGF-β receptor degradation, thus, effectively decreasing or abolishing TGF-β 
signaling (24,25). The increased TGF-β R-1 degradation is mediated by an interaction between 
the receptor and the scaffolding domain of cav-1; the decreased availability of the activated 
TGFβR-1 diminishes the phosphorylation of Smad2/3 and disrupts its interaction with Smad4 
and its subsequent nuclear translocation (26). 
 
The possible participation of cav-1 in the pathogenesis of fibrotic diseases was first suggested 
by Tourkina et al. (27) who demonstrated that cav-1 knock-down in vitro resulted in a 5-fold 
increase in COL1A2 gene expression by normal human lung fibroblasts, whereas, increased 
cav-1 expression caused a reduction in collagen production. A recent study (28) described a 
marked reduction of cav-1 expression in lung tissues and in lung fibroblasts from patients with 
idiopathic pulmonary fibrosis compared to cells from normal lungs. These authors also 
demonstrated that induction of cav-1 expression markedly ameliorated bleomycin-induced 
pulmonary fibrosis and suppressed TGF-β1-induced stimulation of extracellular matrix 
production in cultured fibroblasts. 
 
Based on these observations, we raised the question of whether cav-1 is involved in the 
pathogenesis of tissue fibrosis in SSc. Here, we present evidence supporting the hypothesis 
that cav-1 plays a role in the pathogenesis of tissue fibrosis in SSc. Furthermore, our results 
suggest that an increase of cav-1 function employing a cell membrane permeable cav-1 
scaffolding domain peptide may be a novel therapeutic approach to limit the progression of 
tissue fibrosis in SSc. 
 
Methods 
 
Patients 
 
 
 
 
Full thickness skin biopsies were surgically obtained from three patients with SSc of recent 
onset (<18 months from the appearance of clinically detectable skin induration) and three 
normal controls with IRB approval. The SSc patients satisfied the criteria for the classification 
of SSc (29) and had the diffuse cutaneous clinical subset of the disease as defined by LeRoy 
et al. (30). Skin biopsies were obtained from the leading edge of the lesion on the forearms. 
The tissues remaining after diagnostic histopathology were used for fibroblast isolation and 
for immunohistology. Paraffin embedded sections from surgical open lung biopsies from two 
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patients with SSc associated pulmonary fibrosis and from one autopsy from a patient with SSc 
pulmonary hypertension were obtained. The histopathological examination of skin showed the 
typical changes of SSc. The two lung biopsies displayed the typical features of non-specific 
interstitial pneumonitis. The lungs from the autopsy case showed typical histopathological 
findings of pulmonary arterial hypertension. 
 
Animals and histopathology studies 
Cav-1 deficient mice were generated as previously described are in the C57Bl/6 genetic 
background (31). Six same gender mice per group were sacrificed at 3 months of age. After 
hair removal with a commercial depilatory, full thickness skin samples were surgically excised 
from the interscapular region of the animals, stretched and pinned in histopathology cassettes 
and fixed in phosphate buffered formalin for 24 h. The lungs were removed and the left lung 
was processed by perfusion of the left pulmonary artery with paraformaldehyde to attain 
fixation of the parenchyma avoiding alveolar collapse or atelectasis as described previously 
(32). The entire right lung was hydrolyzed and used for hydroxyproline assays. Paraffin 
embedded skin and lungs were stained with hematoxylin/eosin and Masson's trichrome 
according to standard procedures. 
 
Hydroxyproline assays 
The collagen content in the lungs and skin of the same animals sacrificed for the histopathology 
studies was determined by hydroxyproline assays. Skin samples obtained from an area adjacent 
to that used for histopathology with a 4mm tissue punch, and the right lung were weighted and 
hydrolyzed in 6M HCl overnight at 110°C for determination of their hydroxyproline content, 
as described (33). 
 
Confocal microscopy studies 
Cav-1 protein was analyzed by immunofluorescence using a anti-cav-1 rabbit polyclonal 
antibody (Santa Cruz Biotechnology, Cambridge, MA). Rabbit IgG (Sigma, St Louis, MO) 
was used as isotype control. For Smad localization studies, cells were fixed and permeabilized 
as described (34). Anti Smad3 antibodies (Upstate, Temecula, CA) were used at a 1:200 
dilution. Secondary antibodies used in the studies were affinity purified sheep FAB' anti rabbit 
IgG conjugated with different fluorochromes (Sigma). Paraffin embedded sections from skin 
and lung were processed as described (35). The primary antibody incubation step was 
performed in a dark humidified chamber over-night at 4 °C and then incubated with the 
secondary antibody (1:200). The unbound antibodies were removed from the section following 
each incubation with 3 changes of PBS for 2 min each. Tissue sections or fixed cells were then 
counterstained with DAPI and analyzed using a Zeiss LSM 510 META Confocal Laser 
Scanning Microscope System and software. The two channels were recorded simultaneously 
if no cross-talk could be detected. The breakthrough of the DAPI signal into the red and the 
green channels was recorded separately and subtracted from the DAPI blue channel. Each 
image was scanned 8 times to separate signal from noise. Panels were assembled using 
Photoshop software without any RGB modification. 
 
Cell culture 
 
 
Fibroblasts from normal and SSc dermis were cultured in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 10% FBS, antibiotics and glutamine (complete medium) until 
confluent. Fibroblasts from cav-1 knockout or WT mice were obtained by subculturing full 
thickness skin biopsies from age and sex matched animals. Both human and mouse fibroblasts 
were used at passages 4 to 10. 
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RNA isolation and quantitative real time PCR 
Fibroblasts were harvested with trypsin/EDTA, washed in PBS and then processed for RNA 
extraction (RNAeasy kit; Quiagen, Valencia, CA) according to the manufacturer's protocol, 
including a genomic DNA digestion step. Total RNA (2 μg) was reverse-transcribed using 
Super-script-II reverse transcriptase (Invitrogen). Real-time PCR was performed using SYBR 
green Master mix chemistry employing a standard amplification protocol on a Bio-Rad MyiQ 
real-time PCR system (Bio-Rad, Hercules, CA). Reactions were conducted as described (36). 
To confirm the amplification specificity, the PCR products were subjected to melting 
temperature dissociation curve analysis. No amplification and no template controls were 
examined in parallel. The differences in the number of mRNA copies in each PCR reaction 
were corrected for endogenous control transcript levels; the control experiment levels were set 
as 100 and all the other values expressed as a multiple thereof. 
 
Primer sequences 
All primers were designed using Primer Express (Applied Biosystem) and validated on NCBI 
database for specificity (Table 1). 
 
ELISA 
 
 
SearchLight® proteome arrays (Pierce Biotechnology, Woburn, MA) were performed to 
measure the levels of IL-6 and MMP-3 in supernatants from mouse fibroblasts and the levels 
of MMP-3 and PAI in tissue culture supernatants form human fibroblasts as described (36). 
Briefly, samples were diluted 1:5, 1:50 or 1:1000 before a one h incubation on the array plates, 
which had been pre-spotted with capture antibodies specific for each protein. Plates were 
decanted and washed three times before adding a mixture of biotinylated detection antibodies 
to each well. After incubating with detection antibodies for 30 min, plates were washed three 
times and incubated for 30 min with streptavidin-horseradish peroxidase. Plates were again 
washed before adding SuperSignal® Femto Chemiluminescent substrate. The plates were 
immediately imaged using the SearchLight imaging system and data were analyzed using 
ArrayVision software. 
 
Western Blot analysis 
Intracellular proteins in whole cell lysates were obtained by lysing the confluent cells in 100 
mm dishes as described (36). Fifty μg of protein were used per each sample. Primary antibodies 
used in the different experiments were: cav-1 polyclonal rabbit antibody (Santa Cruz) at a 
1:1000 dilution, collagen I polyclonal rabbit antibody (Rockland, Gilbertsville, PA) at a 1:3000 
dilution in 5% milk TBST overnight at 4 °C; rabbit anti connective tissue growth factor (CTGF) 
polyclonal antibodies (ABCAM, Cambridge, MA), and rabbit anti-phospho-Smad 2/3 
polyclonal antibodies (Chemicon International, Temecula, CA). Anti rabbit HRP conjugated 
antibodies at a 1:3000 dilution were used as secondary antibodies. To verify equal loading and 
transfer the membranes employed for intracellular protein blots were stripped using Pierce 
RESTORE™ stripping buffer and re-probed with rabbit anti human actin antibodies 
(Rockland) at a 1:1000 dilution in 5% milk TBST overnight at 4 °C. 
 
Treatment of cells with cell permeable peptides 
It has been demonstrated that cav-1 regulates TGF-β/Smad signaling through an interaction 
between the TGFR-1 receptor and a peptide corresponding to the scaffolding domain of cav-1 
(DGIWKASFTTFTVTKYWFY) (26). Confluent cells between passages 4 and 9 were treated 
for 24 h with either penetratin peptide, a 16-amino acid cell permeable peptide corresponding 
to the homeodomain of the Drosophila transcription factor antennapedia 
(RQPKIWFPNRRKPWKK) or with a peptide consisting of the fusion of the antennapedia 
peptide and the peptide corresponding to the scaffolding domain of cav-1 (32). This fusion 
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peptide, referred to as cav-1p, was used at 2.5 and 5 μM final concentrations. Fibroblasts were 
incubated in duplicate for each experiment for 24 h with or without 10 ng/ml TGF-β. Following 
24 h incubation with or without TGF-β, one experimental plate was harvested and processed 
for RNA extraction for real time PCR and the other was processed to obtain cell lysates for 
Western blots. Tissue culture supernatants were collected to analyze collagen production by 
Western blot. 
 
Statistics 
 
 
The resulting data were subjected to two-tailed t-test for statistical significance. A p value of 
<0.05 was considered significant. 
 
Results 
 
Decreased levels of Cav-1 in affected SSc lung 
Affected tissues from patients with SSc-related pulmonary fibrosis and PAH displayed reduced 
cav-1 immunofluorescence compared to normal lungs (Figure 1). The reduction in fluorescence 
staining for cav-1 was observed in the thickened alveolar septa typical of SSc alveolitis (Figure 
1B). This reduction was even more apparent in the neointima of pulmonary arteries in lungs 
from SSc patients affected by PAH (Figure 1C) and in the interstitium of a lung section from 
a region where the normal lung architecture has been replaced by fibrotic tissue (Figure 1D). 
In contrast, intense cav-1 immunofluorescence was observed in histopathologically non- 
affected areas of SSc lung tissues from the same patients (Figure 1E). Quantitative analysis of 
the integrated density of fluorescence in three different fields per each type of lung involvement 
represented in panels A-E was performed employing Image J software. The ratio between cav-1 
immunofluorescence staining (green fluorescence) and the number of cells in the sample as 
assessed by DAPI staining of their nuclei was 1.95 in normal lung and 2.1 in histopathologically 
non-affected SSc lung biopsies, compared to 0.79 in the alveolitis sections, 0.60 in the PAH 
sections, and 0.66 in the late fibrotic lesions sections. These data are shown in Figure 1F. Hence, 
the three types of SSc lung involvement analyzed showed, respectively, 59%, 69% and 66% 
decrease in relative cav-1 immunofluorescence levels compared to either normal lung tissue 
or to histopathologically non-affected areas of SSc lung. 
 
Cav-1 levels are decreased in SSc skin and in SSc dermal fibroblasts 
The expression of cav-1 observed by confocal microscopy was markedly reduced in SSc 
affected skin (Figures 2A-D). We then compared by quantitative analysis of the integrated 
density of fluorescence the levels of cav-1 in three normal and three SSc skin biopsies. The 
results indicated that the cav-1/DAPI immunofluorescence ratio in the SSc affected skin was, 
in average, less than 50% than that observed in normal skin (Figure 2E). To confirm these 
results we studied in vitro cultured fibroblasts derived from SSc lesional skin because these 
cells recapitulate the most important molecular alterations responsible for the fibrotic 
phenotype observed in SSc skin in vivo. In these studies we compared the amount of cav-1 
protein between SSc and normal dermal fibroblasts by immunofluorescence analysis (Figure 
2F) and Western blot (Figure 2G). Both studies showed a dramatic decrease of cav-1 in SSc 
dermal fibroblasts compared to normal dermal fibroblasts. 
 
TGF-β downregulates cav-1 expression in vitro 
To investigate whether the potent profibrotic growth factor, TGF-β may be involved in the 
observed reduction of cav-1 in affected SSc tissues we examined the effects of TGF-β on cav-1 
expression in cultured human normal dermal fibroblasts. As shown in Figures 2H, and 2I, we 
observed a profound decrease in cav-1 mRNA and protein levels following 24 h incubation 
with 10 ng/ml human recombinant TGF-β. 
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Cav-1 knockout mice display pulmonary and dermal fibrosis and increased collagen content 
To investigate whether the observed reduction of cav-1 in affected SSc lung and skin biopsies 
in vivo and in SSc cultured fibroblasts in vitro could play a role in the pathogenesis of tissue 
fibrosis we analyzed by histopathology the skin and lungs of mice lacking cav-1 expression. 
We observed that cav-1 null mice lungs had increased staining in the interstitium, indicating 
an increase of the collagen content in the lungs. The histopathologic analysis of paraffin 
embedded sections of skin biopsies from the same mice showed an increase in the thickness 
of the dermis which was accompanied by an increase in collagen staining (Figure 3A). 
Hydroxyproline assays on lung and skin from six 12-week old cav-1 knockout mice and six 
matched wild type (WT) littermates showed that the collagen content of cav-1 null mice lungs 
was 2.5 fold greater than that of WT animals (average cav-1 null = 0.86 μg/mg; WT = 0.35 
μg/mg; p<0.001) and that skin of cav-1 null mice contained 2.4 fold more collagen that skin 
from WT mice (average cav-1 null = 6.8 μg/mg; WT = 2.8 μg/mg; p=0.002) (Figure 3B). 
 
Cav-1 null fibroblasts display a profibrotic phenotype in vitro 
To determine whether the skin fibroblasts obtained from cav-1 null mice recapitulate in vitro 
the molecular events associated with a profibrotic phenotype, we examined collagen, α-smooth 
muscle actin (α-SMA) and metalloproteinase (MMP) gene expression in cav-1 null fibroblasts 
by real time PCR. We observed a 2-fold increase in col1a1 transcript levels, a 3.5 fold increase 
in α-SMA expression and an 80% reduction in MMP-3 mRNA (Figure 3C). Furthermore, we 
also found an increase in IL-6 and a reduction in mmp-3 protein levels, as determined by ELISA 
of tissue culture supernatants (Figure 3D). 
 
A cav-1 cell permeable peptide downregulates SSc fibroblast collagen production and 
suppresses the upregulation of TGF-β inducible genes in vitro 
We next set out to examine whether cav-1p, a cell permeable cav-1 scaffolding domain peptide, 
previously shown to be able to inhibit TGF-β pathway activation and to mimic cav-1 function 
in a rat model of PAH (26,32), could exert an antifibrotic effect on SSc fibroblasts. We analyzed 
the effects of the cav-1p on SSc fibroblasts either under control conditions or following 
stimulation with TGF-β. We found that treatment of SSc dermal fibroblasts with cav-1p caused 
a reduction in their collagen expression both at the basal level and following TGF-β stimulation 
(Figure 4A). Furthermore, gene expression analysis of CTGF, a potent profibrotic TGF-β 
inducible gene, showed that treatment with cav-1p reduced its basal level of expression and 
abrogated the stimulation normally induced by TGF-β (Figure 4A). The results shown in Figure 
4A were confirmed at the protein level for both proteins. Western blots for type I collagen 
indicated that incubation with 2.5 or 5 μM cav-1p caused a profound reduction in basal collagen 
production (Figure 4B). Furthermore, we also observed that 5 μM cav-1p abrogated TGF-β 
induced type I collagen stimulation (Figure 4B). These effects were not caused by cellular 
toxicity induced by the cav-1p as cell viability assays did not show any differences between 
treated and untreated cells at 18 and 24 h time points (Figure 4C). Western blots for CTGF of 
the cell lysates from SSc fibroblasts incubated with TGF-β for 24 or 48 h confirmed at the 
protein level the inhibitory effects of 24h cav-1p treatment observed at the mRNA level (Figure 
4D). PCR analysis and immunofluorescence studies of SSc fibroblasts indicated that the basal 
expression of α-SMA transcripts and α-SMA containing stress fibers were reduced by treatment 
with 10 μM cav-1p and that treatment with the peptide inhibited the TGF-β induced increased 
levels of α-SMA mRNA and stress fibers (Figures 5A and 5B). The cav-1 peptide also reduced 
the effects of TGF-β on the production of plasminogen activator inhibitor 1 (PAI1) and 
increased the production of MMP-3 regardless of TGF-β stimulation, as demonstrated by 
ELISA of the tissue culture supernatants (Figure 5C). 
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A cav-1 cell permeable peptide inhibits TGF-β pathway activation through suppression of 
Smad3 phosphorylation 
To gain a mechanistic insight in the observed inhibitory effects of the cav-1p on TGF-β pathway 
activation, we analyzed Smad3 phosphorylation in SSc fibroblasts following TGF-β 
stimulation. We observed that cav-1p inhibited the TGF-β induced phosphorylation of Smad3 
as early as 5 min following TGF-β stimulation. The inhibition was more pronounced at 15, 30 
and 60 min following TGF-β (Figure 6A). To examine whether cav-1p also reduced the 
translocation of activated Smad3/4 complexes from the cytoplasm to the nucleus we analyzed 
by immunofluorescence the cellular localization of Smad following incubation of SSc dermal 
fibroblasts with TGF-β. We observed that the expected nuclear localization of Smad3 at 60 
min following TGF-β stimulation was almost completely abrogated in the presence of 5 μM 
cav-1p (Figure 6B). 
 
Discussion 
 
Since the discovery of the potent profibrotic and immunomodulatory activities of TGF-β, this 
growth factor has been recognized as one of the most important molecules in the pathogenesis 
of SSc and other fibroproliferative diseases (1,9-20). The classic pathway of TGF-β signal 
transduction involves the ligand-bound TβRII which recruits the TGF-βI receptor (TβRI) and 
then transphosphorylates specific serine and threonine residues in a short (30 amino acid) 
regulatory sequence known as the GS region (37,38). Signaling from the phosphorylated 
TβRI receptor to the nucleus then occurs through the Smad family of proteins (39). Smad2 or 
Smad3, two of the five receptor activated Smads (RSmads), bind to the activated TGF-β 
receptor complex and become phosphorylated, allowing the formation of a complex with the 
co-Smad, Smad4, a cytoplasmic protein which translocates the Smad complex through nuclear 
membrane pores into the nucleus. Once in the nucleus, Smad3/Smad4 complexes act as 
transcription factors, binding with the help of intranuclear transcriptional partners to specific 
DNA binding sites in the promoter regions of target genes and activating their expression. To 
further add to the complexity of the TGF-β activation and signaling cascades, it has been 
recognized that there are numerous other non-Smad mediated events involved in TGF-β 
functions and effects (40,41). Furthermore, it has also been recently demonstrated that other 
non-TGF-β dependent pathways may be necessary for the expression of the full SSc fibroblast 
phenotype. For example, Chen et al. (42) found that the overexpression of CTGF and α-SMA 
in SSc fibroblasts was independent of TGF-β signaling, as it could not be abolished by treatment 
of the cells with a specific inhibitor of ALK-5, the receptor involved in the canonical TGF-β 
activation cascade. 
 
Another important mechanism of regulation of TGF-β activation involves the intracellular 
degradation of the activated TGF-β receptor complex. The important role of cav-1 in this 
regulation has recently been recognized (23-26) and it has been suggested that alterations in 
this process may participate in the initiation and progression of tissue fibrosis (27,28). Thus, 
the purpose of the present studies was to examine the role of cav-1 in the pathogenesis of tissue 
fibrosis in SSc. We demonstrate here that the levels of cav-1 in affected SSc lung and skin 
were substantially lower in comparison with normal tissues. Interestingly, our findings that 
cav-1 expression was not reduced in histopathologically non-affected areas of SSc lungs 
indicate that reduction of cav-1 expression may be a specific component of the actual pathologic 
process rather than the result of a generalized manifestation of SSc. Additionally, our 
observations that cav-1 is also low in lesional SSc skin indicates that regardless of the anatomic 
site, a reduction in cav-1 likely represents a marker of the pathologic process in SSc. 
 
To explore the functional effects of decreased cav-1 expression in vivo, we employed cav-1 
knockout mice (31) and performed a detailed histopathologic analysis of skin and lung tissues 
from these mice. In these studies we found that the lack of cav-1 expression was accompanied 
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by skin and lung fibrosis supporting the notion that the observed decreased expression of cav-1 
in SSc tissues may participate in the fibrotic process rather than being only an epiphenomenon. 
Furthermore, we found that cav-1 null fibroblasts displayed a profibrotic phenotype 
characterized by an increased expression of type I collagen, α-SMA and IL-6 and decreased 
production of MMP-3. In support of our observations are the results of a recent study (28) 
which showed that induced overexpression of cav-1 in vitro employing an adenoviral vector 
suppressed the expression of various genes encoding extracellular matrix molecules as well as 
TGF-β induced α-SMA upregulation in the MRC-5 fibroblast line. 
 
To further examine the role of decreased cav-1 expression in the development of tissue fibrosis 
we explored the effects of increasing cav-1 function in SSc fibroblasts on the expression of 
genes encoding various key proteins participating in the process of pathologic fibrogenesis. 
The numerous and potentially serious difficulties encountered with the clinical application of 
virally-mediated gene therapy approaches (43-47) has stimulated the search for alternative 
methods of delivery of therapeutic proteins into cells. One of the most promising approaches 
is the utilization of novel cell permeable carriers capable of shuttling small peptides and 
proteins inside cells (48). One such carrier which has been utilized extensively is the small 
peptide, penetratin. Hence, we treated SSc fibroblasts in vitro with a cell permeable cav-1 
scaffolding domain peptide (cav-1p), previously shown to be capable of increasing the 
intracellular bioavailability of cav-1 (26,32), and examined whether the reconstitution of 
intracellular cav-1 function resulted in a modulatory effect on the profibrotic phenotype of SSc 
fibroblasts. We found that the administration of cav-1p in vitro to SSc fibroblasts caused a 
significant reduction in the basal level of COL1A1 production, as well as a reduction in CTGF 
protein levels and α-SMA containing stress fibers. Of further interest, was the observation that 
the TGF-β induced upregulation of COL1A1, CTGF and α-SMA was strongly inhibited by 
treatment of SSc cells with cav-1p. Subsequently, we demonstrated that the inhibitory effects 
of cav-1p on TGF-β pathway activation were associated with the inhibition of Smad3 
phosphorylation and of its nuclear translocation. 
 
However, it should be noted that in the absence of TGF-β stimulation SSc fibroblasts did not 
show appreciable nuclear accumulation of Smad3. Although these results are in contrast with 
previously published data on Smad3 nuclear localization in SSc fibroblasts (19), they support 
the participation of non-Smad3-mediated pathways in the activation of the SSc fibroblast 
phenotype as suggested by Chen et al (42) and suggest that in the absence of exogenous TGF- 
β stimulation cav-1p could function in a TGF-β/Smad independent pathway. 
 
In summary, the studies described here support strongly the hypothesis that decreased 
expression of cav-1 in SSc tissues plays a role in the development and progression of tissue 
fibrosis by mediating a sustained activation of the TGF-β pathway. Furthermore, we 
demonstrated that an in vitro intervention capable of increasing cav-1 function employing a 
cell permeable cav-1 peptide, reverted the profibrotic phenotype of SSc fibroblasts in vitro an 
that this effect was mediated by the suppression of the cascade of events induced by TGF-β 
receptor ligation as shown by the abrogation of Smad3 phosphorylation and nuclear 
translocation. 
 
These results suggest that restoration of cav-1 function in vivo employing cell permeable cav-1 
peptides may be effective to prevent the progression and limit the extension of tissue fibrosis 
in SSc. Future studies should be performed to fully assess the long-term safety and effectiveness 
of cav-1p administration in vivo as a novel therapeutic approach for SSc. 
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Figure 1. Confocal microscopy imaging of cav-1 in SSc lung 
A: Normal lung immunostained for cav-1. Note the homogeneous green staining for cav-1 on 
the surface of each alveolar cell of the alveolar wall with an evident cell membrane pattern. 
The nuclei of all cells are stained with DAPI and appear blue. B: SSc lung immunostained for 
cav-1. Note that in contrast with A, there is non- homogeneous staining of cav-1 with markedly 
reduced levels of immunofluorescence in the involved alveolar septa as indicated by numerous 
cells (blue nuclei) without any detectable cav-1 staining in their surface. C: Pulmonary artery 
in the lung form a patient affected by SSc-related pulmonary artery hypertension. Note the 
reduced cav-1 immunofluorescent signal in most cells (blue nuclei) of the vessel wall. D: A 
fibrotic area of a lung from a SSc patient. Note the absence of cav-1 staining in many stromal 
 
Arthritis Rheum. Author manuscript; available in PMC 2009 October 28. 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
Galdo et al. Page 13 
 
cells (arrows). The images of each panel are representative of tissue samples from three 
different patients. E: Histopathologically non-affected area of lung from the same SSc patient 
shown in panels B and D. F: Bar graph of the ratio between cav-1 and DAPI integrated density 
of fluorescence (IDF) in panels A-E. (N=3; * = p<0.05 vs. A). 
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Figure 2. A-D: Confocal microscopy imaging of cav-1 in SSc skin 
Non specific auto fluorescence of the DAPI channel is shown to display skin anatomy of (A) 
normal skin biopsy and (B) SSc skin biopsy. Note the tightly packed collagen fibrils in the 
lower dermis of the SSc biopsy. C: Confocal microscopy of the same section shown in A 
stained for cav-1 (green) and DAPI (Blue). Note the presence of intense cav-1 immunostaining 
surrounding almost every cell in the dermis. D: Same section shown in B stained for cav-1 
(green) and DAPI (blue). Note that most cells (blue nuclei) do not show any detectable cav-1 
staining (green) in their surface. The images shown in each panel are representative of tissue 
samples from three different patients. E: Quantitative analysis of fluorescence. Bar graph of 
the ratio between cav-1 and DAPI integrated density of fluorescence (IDF) in panels C and D. 
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(*= p<0.05). F-G: Cav-1 expression in SSc fibroblasts in vitro. F: Immunofluorescence 
analysis of cav-1 expression (red) in confluent normal and SSc fibroblasts (both at passage 5). 
The figure shows a representative result from experiments performed with two normal and two 
SSc cell lines each in triplicate. Nuclei are stained with DAPI (Blue). G: Cell lysates from two 
SSc dermal fibroblast cell lines and two normal dermal fibroblast cell lines were analyzed by 
Western blot for cav-1. Antibodies directed against β-actin were used as control for equal 
protein loading. H-I: Cav-1 expression following TGF-β stimulation. H: mRNA levels for 
cav-1 were analyzed in two normal human fibroblast lines by real-time PCR following 24 h 
incubation with 10ng/ml TGF-β. Each bar represents the average ± SD of three different PCR. 
Cav-1 mRNA levels of the first line were arbitrarily set to 100 and all the other values calculated 
as multiples thereof. ** = p<0.01. I: Cell lysates from the same two human dermal fibroblast 
lines analyzed by Western blot for cav-1 following the same conditions described in panel H. 
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Figure 3. A-B: Cav-1 knockout mice display increased collagen content in their lungs and skin 
A. Masson's Trichrome staining of collagen in the lung interstitium (upper panel) and in the 
skin (lower panel) of wild type (WT) and cav-1-/- lung (CAV -/-) (upper panel: 400× lower 
panel: 200×). B: Hydroxyproline assays of lungs from 6 cav-1-/- and 6 WT 12-week-old mice. 
Each symbol (squares for WT and triangles for cav-1-/-) represents one animal. Results are 
shown as μg of hydroxyproline /mg of wet weight of the tissue. Paired t-test analysis showed 
p<0.001 for both. C-D: Cav-1-/- fibroblasts display a profibrotic phenotype. C: mRNA levels 
for COL1a1, MMP-3 and α-SMA were analyzed by quantitative real time PCR in WT (white 
bars) and cav-1-/- (black bars) fibroblasts. Each bar represents average ±SD of three different 
PCR. The mRNA levels of the WT line were arbitrarily set to 100 and all the other values 
calculated as multiples thereof. The transcript levels were corrected for 18S RNA levels. * = 
p < 0.05; ** = p < 0.005. D: Tissue culture supernatants from confluent WT or cav-1-/- 
fibroblasts were analyzed for IL-6 and MMP-3 by multiplex ELISA using Pierce Searchlight 
Multiplexed Proteome Arrays. Culture media from three separate WT and cav-1-/- cell lines 
were analyzed in duplicate; *** = p< 0.0001. 
 
 
 
 
 
 
Arthritis Rheum. Author manuscript; available in PMC 2009 October 28. 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
N
IH
-P
A
 A
u
th
o
r M
a
n
u
s
c
rip
t 
Galdo et al. Page 17 
 
 
 
Figure 4. Effects of cav-1p on SSc fibroblast profibrotic phenotype 
A: Real time PCR analysis of COL1A1 and CTGF mRNA from SSc dermal fibroblasts treated 
for 24 h with 10 ng/ml of human recombinant TGF-β in the presence of either 5 μM cav-1p 
(cav-1p) or 5 μM control peptide (penetratin-AP). mRNA levels for each gene under control 
conditions (penetratin without TGF-β) were set to 100. Other values were then calculated as a 
multiple thereof. Bars represent the average of three different PCR reactions. The results shown 
are representative of three different experiments. * = p<0.05; *** = p< 0.001. B: Western blot 
for collagen I in tissue culture supernatants from SSc fibroblasts treated for 24 h with cav-1p 
or penetratin alone (Control) with and without TGF-β. C: Cell viability of confluent dermal 
fibroblast monolayers assessed by WST-1 assay following 18, 20 or 24 h treatment with cav-1p, 
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or penetratin alone (CTRL). NS: Not statistically significant. D: Western blot for CTGF in cell 
lysates from SSc fibroblasts following 24 h and 48 h TGF-β incubation in the presence of either 
control peptides (-) or cav-1p (+). 
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Figure 5. 
A: Real time PCR analysis of mRNA levels of α-SMA from SSc dermal fibroblasts treated for 
24 h with 10 ng/ml of human recombinant TGF-β in the presence of either 5 μm cav-1p (cav-1p) 
or 5 μm control peptide (penetratin-AP). mRNA levels for each gene under control conditions 
(penetratin without TGF-β) were set to 100. Other values were then calculated as a multiple 
thereof. Bars represent average of three different PCR reactions. The results shown are 
representative of three different experiments. *** = p< 0.001. B: Immunofluorescence for α- 
SMA in SSc cells in the same experimental conditions described in A. Note the decreased 
number of fibroblasts expressing stress fibers in the presence of cav-1p both at basal level and 
following TGF-β stimulation. Original magnification 200×. C: ELISA of tissue culture 
supernatants for PAI and MMP-3. The results shown are the average of two different cell lines, 
each assayed in duplicate at three different dilutions. * =p<0.05; ** p= 0.01. 
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Figure 6. 
A: Cell lysates from SSc fibroblasts prepared 5, 15, 30 and 60 min following TGF-β stimulation 
(10ng/ml) in the presence or absence of cav-1 peptides were examined by Western blot using 
an antibody specific for phosphorylated Smad2/3. To document equal loading and transfer, the 
same membrane was stripped and reblotted with β-actin (β-ACT) antibodies B: Intracellular 
immunolocalization of total Smad3 in SSc fibroblasts following 60 min incubation with cav-1p 
or control peptide (CTRL) in the presence or not of TGF-β (10ng/ml). Note the marked nuclear 
accumulation of Smad3 following TGF-β treatment and the almost complete abrogation of this 
accumulation in cells treated with cav-1p. Original magnification 1000×. 
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Table 1 
Oligonucleotides employed for Sybr-green quantitative RT-PCR 
 
HUMA
N 
  
β -ACT TTGCCGACAGGATGCAGAA GCCGATCCACACGGAGTACTT 
COL1A1 CCTCAAGGGCTCCAACGAG TCAATCACTGTCTTGCCCCA 
CAV-1 CGACCCTAAACACCTCAACGA TCCCTTCTGGTTCTGTCA 
CTGF GTGTGCACTGCCAAAGATGGT TTGGAAGGACTCACCGCTG 
α-SMA TGTATGTGGCTATCCAGGCG AGAGTCCAGCACGATGCCAG 
MOUSE   
18S GAAACGGCTACCACATCCAAGGA
A 
ACAATACAGGACTCTTTCGAGCCCTGTA
A col1a1 CTGGCCCAGGCAGTCAGAT GGGTTTGCTACAACATGGGCTA 
mmp3 GTGTGCACTGCCAAAGATGGT TTGGAAGGACTCACCGCTG 
α-SMA GTGGCCCCTGAAGAGCATC AATCTGGGTCATTTTCTCCCG 
 
